O
OneSource
Vertically integrated biopharmaceutical company
About OneSource
Stelis Biopharma is a leading Contract Development and Manufacturing Organization (CDMO) that specializes in the production of biologics, which are drugs derived from living organisms. The company serves a broad range of clients, including top biopharmaceutical companies, and operates primarily in the Asia-Pacific (APAC) region, where it boasts one of the highest CDMO capacities.
Stelis Biopharma's business model revolves around supporting the entire lifecycle of a biologic product, from development to market. This includes the production of both drug substances and drug products. The company operates two state-of-the-art facilities in Bangalore, India, which together offer around 85,000 square meters of process development and manufacturing space. These facilities are equipped to handle a variety of production modalities, including mammalian and microbial processes.
The company generates revenue by providing end-to-end product development and manufacturing services. This includes small-scale clinical and commercial manufacturing, as well as quality control. Stelis Biopharma prides itself on its commitment to quality and regulatory compliance, and its facilities have been designed in consultation with international regulatory agencies, including the US Food and Drug Administration (FDA).
In summary, Stelis Biopharma is a trusted partner in the biopharmaceutical industry, offering comprehensive product development and manufacturing services. The company's commitment to quality, regulatory compliance, and client collaboration sets it apart in the competitive CDMO market.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2013
- Headquarters
- Bengaluru, India
- Employees
- 373
- Open positions
- None listed
- Dealroom signal
- 28.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Became $1B as Subsidiary, Biotech and Pharma, Hard Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SECONDARYOther financing | Nov 2025 | $0 | — | Undisclosed | ↗ |
| IPOOther financing | Jan 2025 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for OneSource is 3.7K monthly website visits, down 30.2% over the last three months. OneSource's team declined 15.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Strides Pharma Science
Series B and later11 investors entered at this stage
TPG Growth
Route One- MFMankekar Family
- TIThink Investments
HBM Healthcare Investments
Enam Holdings
SBI Life Insurance Company
Param Capital
WhiteOak Capital Asset Management
Motilal Oswal Mutual Fund
IIFL
Other known investors1 additional known investor
360 ONE Asset
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OneSource on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OneSource’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







